Sentences with phrase «controlling cell differentiation»

Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.

Not exact matches

The current view proposes that stem cell differentiation is controlled by their local environment, the so - called niche.

Varghese and her team showed that they could control the differentiation of human pluripotent stem cells into functional osteoblasts — bone - building cells — simply by adding the molecule adenosine to their growth medium.

Directly or indirectly, Holick points out, «the active form of vitamin D controls up to 200 different genes,» including ones responsible for cell proliferation, differentiation, and death.

Since Yamanaka's breakthrough, dozens of groups have reported other ways of reprogramming cells as well as techniques to control differentiation of stem cells into neurons, cardiovascular cells, and other tissues of interest for regenerative medicine.

The precise balance between the two compounds controls the transition from cell proliferation to differentiation.

JAK1 is part of a well - studied regulatory network of proteins that is involved in the control of cell growth, differentiation, apoptosis, inflammation, and immune response.

There is no question that ability to generate glucose - responsive, human beta cells through controlled differentiation of stem cells will accelerate the development of new therapeutics.

«In normal conditions, the microenvironment is able to control the proliferation, differentiation and migration of the hematopoietic stem cell.

The pair discovered a swath of cells in frog embryos that controls early cell differentiation.

In CRC 873, funded by the German Research Foundation, medical and biological scientists investigate the basic regulatory mechanisms that control the self - renewal and differentiation of stem cells.

«We were able to show that a significant number of these adenomas carry a mutation in a gene that is involved in controlling cell proliferation and differentiation,» Calebiro further explained.

In the case of planarians, the gene egr - 4 seems to perform an early control of cell proliferation as a response to amputation, and be involved later in the early differentiation of brain during regeneration.

Researchers in Japan have shown that modified gold nanoparticles can be used to control the differentiation of stem cells into bone.

However, in developing brain cells, the researchers found TLR3 activation also influences 41 genes that add up to a double whammy in this model — diminished stem cell differentiation into brain cells and increased cell suicide, a carefully controlled process known as apoptosis.

«A better way to grow bone cells: New method allows for more control in the differentiation of stem cells into bone cells.»

The authors uncover the cellular and molecular mechanisms, as well as the gene network regulated by Sox9 during the early steps of skin tumor initiation and demonstrates that Sox9 controls the long term maintenance and expansion of oncogene expressing cells by promoting self - renewing division and inhibiting differentiation.

Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I - Stem — Inserm / AFM / UEVE), in collaboration with CNRS and Paris Descartes University, have recently developed a new approach to better control the differentiation of human pluripotent stem cells, and thus produce different populations of motor neurons from these cells in only 14 days.

This inefficiency is partly due to a poor understanding of the molecular mechanisms controlling the differentiation of these cells.

The microparticles could also provide better control over the kinetics of cell differentiation.

The differentiation of stem cells is largely controlled by external cues, including morphogenic growth factors, in the three - dimensional environment that surrounds the cells.

Previously, in the region that controls the function of the transcription factor that promotes differentiation from ES cells to a specific cell type, bivalent modifications of histones such as the accelerator and brake histone marks for transcription were thought to have coexisted.

Its first target was the regulatory network involved in controlling the differentiation of THP - 1 cells, a line of human leukemia cells used in laboratory experiments.

Song explained the structural knowledge of DNMT3A will allow scientists to control DNA methylation content, gene expression, and cell differentiation — all of which are linked to diseases and finding cures for them.

In turn, the niche cells control the production and also the differentiation of the blood stem cells.

His work has focused on discovering and characterizing novel small molecules that can control various cell fates and functions, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues.

Our work focuses on discovering and characterizing novel small molecules that can control cell fate and function in numerous cell types, including stem cell maintenance, activation, differentiation, and reprogramming in various developmental stages and tissues.

Dynamic regulatory network controlling TH17 cell differentiation / N. Yosef *, A.K. Shalek *, J. Gaublomme *, Y. Lee, A. Awasthi, H. Jin, C. Wu, K. Karwacz, S. Xiao, M. Jorgolli, D. Gennert, R. Satija, A. Shakya, D.Y. Lu, J.J. Trombetta, M. Pillai, P.J. Ratcliffe, M.L. Coleman, M. Bix, D. Tantin, H. Park, V.K Kuchroo, A. Regev.

Finally, I will show how we have combined our results to generate a model of hematopoietic differentiation where specific transcription factors control lineage regulatory regions; our model predicts many already known lineage - controlling factors as well as finds new potential regulators of hematopoietic differentiation such as ATF3 in monocytes and Tcf7l2 and Runx2 in NK cells.

Unexpected positive control of NFκB and miR - 155 by DGKα and ζ ensures effector and memory CD8 + T cell differentiation.

Interplay between FGF2 and BMP controls the self - renewal, dormancy and differentiation of rat neuralstem cells

Initial studies demonstrated that ligation of 4 - 1BB on T cells could deliver costimulatory signals resulting in either increased proliferation or enhanced cytokine secretion and also control clonal expansion and differentiation of effector and memory T cells.

Alpha tubulin is not suitable as a loading control in adipose tissue as expression of tubulin in adipose tissue is very low (Spiegelman and Farmer, Cell, 1982, 29 (1): 53 - 60, «in cells undergoing adipose differentiation actin synthesis decreases by 90 %»).

Title: Interplay between FGF2 and BMP controls the self - renewal, dormancy and differentiation of rat neural stem cells Authors: Sun Y, Hu J, Zhou L, Pollard SM, and Smith A Date: June 2011 Publication Details: J Cell Sci, Jun 1 2011:124 (11); 1867 - 1877

Professor Kyurkchiev's group is currently developing a project on the controlled differentiation of human induced pluripotent stem cells into hematopoietic stem cells and lymphoid cells.

He has been interested in differentiation and growth control throughout his career and is an expert on hematopoietic stem cells, macrophage differentiation, hematopoietic and Maf family transcription factors.

The morphological changes manifested in the cell types linked to larger toepads exemplify cell type differentiation that must be controlled by the physiology of reproduction and properly timed nutrient - dependent reproductive sexual behavior, which probably occurs near the location of the higher perches.

To evaluate whether ABL kinases might regulate the secretion of osteoblast - derived RANKL or OPG leading to osteoclast differentiation, we analyzed RANKL and OPG mRNA abundance in the murine osteoblast cell line 7F2 in response to conditioned medium from control and ABL1 / ABL2 knockdown breast cancer cells.

Embryonic stem cells, Adult stem cells, Reprogramming to pluripotency and lineage conversion, Directed differentiation, Germ cells, Genetic and epigenetic mechanisms, Stem cells in development, Stem cell niche, Cancer stem cells, Disease modeling and drug screening, Stem cell therapy, Clinical studies in regenerative medicine, Tissue engineering and biomaterials, Imaging and diagnostics, Stem cell products, manufacturing, and quality control, Ethical, legal, and social issues Read Journal

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

Research Interests: Molecular control of cell fate from stemness to differentiated skeletal and neuronal cell types; SOX transcription factors; skeletal malformation and degeneration diseases; intellectual disability and autism spectrum disorders; mouse genetic models; human pluripotent stem cell differentiation models in vitro

The origins of many of these and other genes specific to animal processes such as cell adhesion, and social control of cell proliferation, death and differentiation can be traced to genomic events (gene birth, subfamily expansions, intron gain / loss, and so on) that occurred in the lineage that led to the metazoan ancestor, after animals diverged from their unicellular «cousins».

The fellow will drive a new project focusing on molecular mechanisms controlling the identity, self - renewal, and differentiation potential of skeletal stem cells.

Areas of research include biochemical and cellular mechanisms, muscle contractility and cell motility, the genetic control of cell growth and differentiation, and tissue damage and regeneration.

The positioning of the cells controls their genetic program and their differentiation into embryonic or extra-embryonic tissues.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

My recent studies have demonstrated that during tumor progression, TGFβ signaling controls differentiation of CD39 + CD73 + myeloid cells (MC).

Genes involved in DNA damage control and inhibition of DNA synthesis [49], in particular Atm, Chk1 and Chk2, are also highly expressed in ES cells, but decline during differentiation.

usage of model organisms to understand and exploit the mechanisms controlling stem and precursor cell generation, maintenance, activation, recruitment, proliferation, homing and differentiation,

The use of embryonic stem cells as therapeutics requires firm understanding of the mechanisms that control their proliferation and differentiation.